Indications for Olaparib

According to Olaparib's prescribing information, indications approved by the U.S. Food and Drug Administration (FDA) include ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.

1. Ovarian cancer:

(1) Olaparib is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somaticBRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a complete or partial response to first-line platinum-based chemotherapy.

(2)Olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are responsive to first-line platinum Patients who have a complete or partial response to chemotherapy and whose cancer is associated with a homologous recombination deficiency (HRD)-positive status, defined by any of the following: deleterious or suspected deleterious BRCA mutations and/or genomic instability.

(3) Lynparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have a complete or partial response to platinum-based chemotherapy.

2. Breast cancer:

(1) Lynparib is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have received neoadjuvant or adjuvant chemotherapy.

(2) Lynparib is indicated for the treatment of adult patients with deleterious or suspected deleteriousgBRCAm, HER2-negative metastatic breast cancer who have received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have received endocrine therapy or be considered unsuitable for endocrine therapy.

3. Pancreatic cancer:

Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious BRCAm metastatic pancreatic cancer who have not progressed on at least 16 weeks of first-line platinum-based chemotherapy.

4. Prostate cancer:

(1) Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.

(2) Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC) in combination with abiraterone and prednisone or prednisolone.

Lynparza The original drug has been launched in China and has entered the scope of Class B medical insurance, but it is only available to patients who meet the indications. The price of each box of 150mg*56 tablets may be around RMB 6,000. There are price differences for drugs of different specifications. There are also Olaparibgeneric drugs produced overseas. The specifications produced by Bangladesh pharmaceutical factories150mg*120 tablets per box may cost around RMB 4,000 (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the Olaparib original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.